Tag Archives: healthcare

CipherHealth Names New CPO & COO as Company Accelerates Growth

JMI Equity

NEW YORK, May 29, 2019 /PRNewswire/ — As part of its expansion and strategic growth initiative, CipherHealth, the leading patient engagement software company, has announced the new roles of Chief People Officer (CPO) and Chief Operating Officer (COO).

Jennifer Compagni has joined CipherHealth as Chief People Officer and Jake Pyles, the current Chief Financial Officer at the company, is expanding his role to include Chief Operating Officer.

Both will help further CipherHealth’s mission of empowering healthcare providers across the care continuum with integrated patient engagement solutions that improve patient communication and care coordination.

Compagni has an extensive background in corporate business, research, government and educational institutions as an HR executive. She has led HR teams and projects at Warner-Lambert Company, (Pfizer, Adams USA), Antenna Software, Revlon, Alpharma Inc. and The National Research Council of the National Academies. Prior to CipherHealth, Compagni also led the HR organization at SmartLinx Solutions, a growing SaaS company in the workforce management space.

As CPO at CipherHealth, Jennifer Compagni ensures a fluid human resource strategy that supports the overall business plan and strategic direction at the company to attract and retain great talent and make sure employees have an amazing career experience. She also provides strategic leadership by articulating HR needs and plans to the executive management team, shareholders and the board of directors.

“The award winning patient engagement product suite and mission-driven culture attracted me to CipherHealth. The team is an amazing, smart, cohesive group of people working together to enable patients to heal and thrive,” said Compagni.

Jake Pyles, who became CipherHealth’s CFO in August 2018, will now also lead the company’s operations function. With more than twenty-five years of financial and operations experience at various software companies, Pyles has a significant amount of experience with managing high-growth technology companies. Prior to CipherHealth, Pyles spent four years as CFO at Paradigm Geophysical, leading the company to its eventual sale to Emerson Electric.

“We are thrilled with the addition of Jennifer and Jake’s expanded role to help us continue delivering solutions that ensure patients get the best care possible,” said CipherHealth CEO and Co-Founder Randy Cheung.

ABOUT CIPHERHEALTH
Ranked as the top-performing vendor for patient outreach and digital rounding by KLAS in 2019, CipherHealth is a proven healthcare technology partner committed to enhancing communication and care team coordination throughout the patient journey. CipherHealth’s suite of integrated patient engagement solutions empowers healthcare organizations across the continuum to achieve the Quadruple Aim.

Categories: People

Tags:

Eurazeo Patrimoine supports the acquisition of the Belledonne Clinic by C2SGroup

Eurazeo

Paris, May 23,2019 –Eurazeo Patrimoine, Eurazeo’s investment division specializing in real estate and companies holding and operating real assets, announces the acquisition of the Belledonne Clinic,located near Grenoble(Isère, France) by C2SGroup. Created in 1967 in Saint-Martin-d’Hères,near Grenoble, the Belledonne Clinic offers a diversified and comprehensive range of medical services organized around seven activity sectors and particularly, cardiology, cancer surgery and maternity services. It has a capacity of 290 medical beds and 23 procedure rooms, thus becomingC2S Group’s largest clinic. Its reputation is regularly upheld by national private hospitals rankings.

With over 1,900 beds and places and an annual revenue of around €250 million, C2S Group is a major private hospital player in France. It is present in the Rhône-Alpes Auvergne and Bourgogne Franche-Comtéregions, where it has 14 clinics. C2S Group comprises around 710 doctors, who are partners in the Group’s governance, and nearly 2,500 employees. Through its presence in the Center-East region, combining state-of-the-art and local establishments, C2S Group clinics treat over 300,000 patients each year.

Eurazeo Patrimoine has supported C2S’s development since its acquisition in March2018, backing the Group’s external growth policy and helping it invest in capacity and modernization to strengthen the quality and attractiveness of its clinics.Eurazeo Patrimoine contributes financial and human resources and its investment and real estate transformation experience. The integration of the Belledonne Clinic in the Group forms part of this strategy and is a major step in C2S’s development, confirming its position as a key player in the Center-East region.

Renaud Haberkorn,Director of Eurazeo Patrimoine said: “We’re delighted to support C2S in its acquisition of the Belledonne Clinic, a top-tier asset both on operations and real estate level. The management team has demonstrated its ability to rapidly expand the Group, both organically and through instrumental acquisitions.

Eurazeo Patrimoine supports and encourages C2SGroup to achieve its ambitions.”Jean Rigondet, Chairman of C2SGroup, added: “It is essential for patients to be treated by talented practitioners, working together as a team,and to have access to well-organized and broad medical care. The acquisition of the Belledonne Clinic provides us with a high-level, comprehensive technical platform in Greater Grenoble. We’re extremely proud to integrate this reference clinic into our Group.”***

HAVAS PARISMAEL EVINE-mail: mael.evin@havas.comTel: +33 (0)6 44 12 14 91For more information, please visit the Group’s website: www.eurazeo.com Follow us on Twitter,LinkedIn, and YouTube

PRESS CONTACT EURAZEO

CONTACTS CAROLINE COHEN Head of Investor Relations ccohen@eurazeo.comTel.: +33 (0)1 44 15 16 76

VIRGINIE CHRISTNACHT Head of Communicationsvchristnacht@eurazeo.comTel: +33 1 44 15 76 44

About Eurazeo

Eurazeo is a leading global investment company, with a diversified portfolio of €17 billion in assets under management, including nearly €11 billion from third parties, invested in over 300 companies. With its considerable private equity, real estate, private debt and fund of funds expertise, Eurazeo accompanies companies of all sizes, supporting their development through the commitment of its 235 professionals and by offering deep sector expertise, a gateway to global markets, and a responsible and stable foothold for transformational growth. Its solid institutional and family shareholder base, robust financial structure free of structural debt, and flexible investment horizon enable Eurazeo to support its companies over the long term.

Eurazeo has offices in Paris, New York, Sao Paulo,Buenos Aires,Shanghai, London, Luxembourg, Frankfurt and Madrid.

Eurazeo is listed on Euronext Paris.oISIN: FR0000121121 -Bloomberg: RF FP -Reuters: EURA.PA

About C2 SGroup

C2S Group is a multi-regional group of clinics specializing in general medicine and a leader in Auvergne-Rhône-Alpes and Burgundy Franche-Comté, with 14 clinics. C2S Group is currently implementing a sustained acquisition strategy to provide uniform and consistent geographic coverage. Medical practitioners and health professionals in these two regions are closely involved with the Group, which adopts a sustainable and high-performing outlook to human health. It has developed a patient-centric health ecosystem and is committed to offering a comprehensive range of treatments, which anticipates the needs of each patient to provide healthcare excellence.

Categories: News

Tags:

CDPQ provides financing to Medavie Inc. to support advancement of strategic objectives

Cdpq

La Caisse de dépôt et placement du Québec (“CDPQ”) today announced $75 million in financing, which could be increased to $100 million, in the form of a subordinated private debt, to Medavie Inc. (“Medavie”), a Canadian non-profit organization.

Medavie operates Medavie Blue Cross, a premier all-in-one insurance carrier that provides health, dental, travel, life and disability benefits, and administers various government-sponsored health programs, along with Medavie Health Services.

“As a leading health solutions partner in Canada, we are continually reinvesting in our business to help improve the wellbeing of Canadians,” said Bernard Lord, CEO, Medavie. “Our financials are strong and trending for continued growth, and we are pleased to work with CPDQ on an investment structure that best suits our overall needs.”

This transaction, structured directly by CDPQ, will provide Medavie with additional capital as it continues to advance its growth initiative.

“Because of its resilience to economic cycles and the stable returns it generates over a long-term horizon, the insurance sector is perfectly in line with our credit strategy,” said Marc Cormier, Executive Vice-President, Fixed Income, at CDPQ. “CDPQ is delighted to support Medavie, a high-quality organization that has diversified its services to provide health care solutions across Canada.”

In addition to its interests in certain Québec insurers, CDPQ carried out major transactions in this sector abroad in the past few years, with investments in Greenstone in Australia, USI and Sedgwick in the United States, and U.K.-based Hyperion Insurance Group.

ABOUT MEDAVIE

Medavie is a national health solutions partner. Together, with our more than 6,400 employees, we are committed to improving the wellbeing of Canadians.

As a not-for-profit organization, Medavie oversees Medavie Blue Cross, a premier all-in-one benefits carrier and public health program administrator, and Medavie Health Services, a national primary health care solutions organization and the largest private provider of EMS management services in Canada.

We don’t have shareholders. Instead, we are proud to invest in the Medavie Health Foundation to address some of our country’s most pressing physical and mental health care challenges.

ABOUT CAISSE DE DÉPÔT ET PLACEMENT DU QUÉBEC

Caisse de dépôt et placement du Québec (CDPQ) is a long-term institutional investor that manages funds primarily for public and parapublic pension and insurance plans. As at December 31, 2018, it held CA$309.5 billion in net assets. As one of Canada’s leading institutional fund managers, CDPQ invests globally in major financial markets, private equity, infrastructure, real estate and private debt. For more information, visit cdpq.com, follow us on Twitter @LaCDPQ or consult our Facebook or LinkedIn pages.

Categories: News

Tags:

AnaCap acquires leading independent Danish private health insurance business

Anacap

21 May 2019

AnaCap Financial Partners(“AnaCap”), the specialist European financial services private equity firm, today announces the acquisition of a majority stake in SundhedsGruppenA/S (“SundhedsGruppen”), which consists of Dansk Sundhedssikring A/S a leading independent Danish private health insurance provider, and PrimaCare A/S a quality provider of healthcare networks.

AnaCap is acquiring the majority stake in SundhedsGruppen from the Company’s Founders, who will retain a minority.

SundhedsGruppen, provides health insurance and claims management services to clients’ employees and has built a market-leading technological infrastructure that also white labels to other providers in adjunct insurance areas.

The Company has a unique partnership arrangement with medical clinics throughout Denmark that allows for best-in-class provision of healthcare services to its customers’ employees, with a clear focus on specialist support and local availability.

SundhedsGruppen’s proprietary technological platform facilitates accurate identification of optimal healthcare access as well as reporting, feedback and claims management respectively. AnaCap will now look to leverage its deep insurance sector understanding and expertise in improving both technological and digital infrastructure to support enhancements in the customer experience as well as drive growth in new and existing markets.

The business currently provides insurance cover for approximately 250,000 individuals in Denmark, through a client list comprising several of the Nordics’ largest blue-chip companies, having grown from a founder-backed start-up in 2012. Driven by unique market positioning, the Company generated a c.70% CAGR in premiums during the period 2012-2018 vs. a 5% market norm.

AnaCap will also deploy its expertise in the insurance sector to support management’s ambition to grow market share internationally, into the Nordics and wider geographical markets, as well as through additional insurance market channels. The growth of the business will be through organic expansion models as well as identifying attractive bolt-on acquisition opportunities.

Tassilo Arnhold, Managing Director at AnaCap, comments:“AnaCap is delighted to be partnering with SundhedsGruppen.The Company has created a great insurance technology and data-driven platform with a uniquely differentiated insurer challenger proposition, high customer service standards and competitive underwriting. We are confident that our long-standing expertise in backing businesses poised for international growth will actively support this ambitious growth plan and management team, both through technological and operational investments.

” Klaus Busch, Chairman at SundhedsGruppen, comments:“By combining technology with industry expertise and a unique customer proposition, we have built a fast-growing business aiming to grow internationally and into other related industry verticals.One Stephen StreetLondonW1T 1ALPhone: +44-207-070-5250Fax: +44-207-070-5290E-mail: contact@anacapfp.comTransforming Financial Services Across Europe

We are very pleased to have identified AnaCap as a partner for the next stage of our growth and look forward to their support throughout.

”Kent Jensen, CEO at SundhedsGruppen, comments:

“We are extremely proud of the progress we have made in recent years, during which time we have built and strengthened a leading market position. Together with our highly experienced management and staff, we intend to rapidly expand our differentiated offering into new markets, both geographically and sector specific, where there is clear demand for best-in-class private health insurance.”AnaCap was advised during the process by Deloitte, Carey Olsen and Plesner.

The owners of Dansk Sundhedssikring were advised by Nordic M&A, Omera Consulting, and Moalem Weitemeyer Bendtsen.The financial details for this arrangement were not disclosed.

Categories: News

Tags:

CSAM Announces Deal to Acquire KIBI

No Comments

Priveq

The transaction expands CSAM’s leadership in the Nordic niche eHealth market OSLO, Norway(May21, 2019) –CSAM announced today that it has entered into an agreement to acquire KIBI –a medical diagnostics and documentation company with offices in Sweden, Finland and Denmark.

KIBI’s medical imaging solutions are used by more than 100 Nordic hospitals and healthcare centreswithin primary, outpatient and inpatient care.The company is one of relatively few in the Nordics that addresses both DICOM and non-DICOM formats, with full integration of all medical imaging components with various electronic patient record (EPR) systems. KIBI’s headquarters are located in Stockholm,Sweden.

-KIBI’s solutions are a strategic complement to CSAM’s strong offerings in medical imaging and connected healthcare domains, said Sverre Flatby, CSAM CEO. –Together, CSAM and KIBI will offer an unmatched portfolio of scalable, integrated and innovative solutions that provide significant value to our customers and their patients. -I am excited for the opportunity ahead as KIBI and CSAM join our visions, solutions and specialised teams, said Robert Cygnaeus, KIBI CEO.

–CSAM has built a strong reputation as a leader in the Nordics, and I am confident that together we can strengthen our presence further indeliveringnicheeHealth solutions that improve healthcare throughout the Nordics and beyond. The acquisition of KIBI is consistent with CSAM’s strategy to pursue growth through a combination of strategic M&As and organic sales. The transaction is estimated to close by the end of May.

-KIBI’s specialised solutions and highly skilled employees are a strong fit with CSAM’s and will help us achieve our short-and long-term growth ambitions, said Flatby. -With this acquisition, CSAM expands its position across the Nordics, increasing our customerbase in Denmark, Finland and Sweden.

CSAM has been a leading provider of medical imaging and connected healthcare solutions in the Nordics for more than a decade. The company works closely with healthcare professionals and organisations to develop software solutions that deliver the highest value for their operations.

About CSAM

CSAM has established itself as a leading Nordic niche player in the specialised eHealth market with a unique blend of best-in-class innovative technology, and outstanding human skills. The company’s diverse portfolio of software solutions enables healthcare providers to access relevant clinical information at the point of care. CSAM’s commercial headquarters are located in Oslo, Norway. The company also has local offices in Stockholm, Karlstad, Gothenburg, Helsinki, Oulu, Tampere, Tromsø and Warwickshire, as well as a wholly owned software engineering subsidiary in the Philippines.A privately-owned company backed by strong financial partners, CSAM aspires to achieve continued growth both organically and through selected mergers and acquisitions. For more information, visit www.csamhealth.com.

For more information, please contact:

Sverre Flatby, CEOJennifer Goode, Communications Directorsverre.flatby@csamhealth.comjennifer.goode@csamhealth.com+47 9159 9159+1-705-760-0782KIBI contact:Robert Cygnaeus, CEOAnn-Christine Jungmar, CCOrobert.cygnaeus@kibi.seann-christine.jungmar@kibi.se+46 58 23951+46 70912 31 11

Categories: News

Tags:

Cala Health Raises $50 Million Series C Funding

Baird Capital

BURLINGAME, Calif.–(BUSINESS WIRE)–Cala Health, Inc., a bioelectronic medicine company developing wearable therapies for chronic disease, today announced it has completed a $50 million Series C financing. Cala Health will use the funds to introduce Cala TrioTM, a breakthrough therapy for hand tremors in people with essential tremor, to the market as well as expand its therapeutic pipeline. As part of the financing, industry veteran Stacy Enxing Seng will be joining Cala Health’s team as an Independent Director and Board Chair.

“We are excited to continue partnering with Cala Health on its journey to support patients with chronic disease with wearable neuromodulation therapies”

Tweet this

New investors in the Series C financing include Novartis, Baird Capital, LifeSci Venture Partners, TriVentures, and others. All existing investors participated in the round, including Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Lux Capital, Lightstone Ventures, Action Potential Venture Capital, dRx Capital, and GV.

“We are excited to continue partnering with Cala Health on its journey to support patients with chronic disease with wearable neuromodulation therapies,” said Neil Tiwari, General Partner, dRx Capital, a Novartis & Qualcomm joint investment company.

Nicole Walker, General Partner at Baird, added “Cala Health is advancing neuromodulation therapy options without the need for surgery, using body-worn electronics. Baird is thrilled to invest in this field and in the company’s future growth.”

“We are delighted to work with such a strong team of investors and advisors who share our vision for the future of bioelectronic medicines. This financing follows exciting momentum from the past year, including receiving De Novo clearance from the Food and Drug Administration for our therapy for essential tremor and announcing a licensing agreement and ongoing collaboration with Partners Healthcare Innovation and its affiliate, Massachusetts General Hospital,” said Kate Rosenbluth, PhD, Founder and CEO, Cala Health.

Cala Health is preparing for the limited release of the prescription Cala Trio therapy, including an innovative commercial strategy that delivers prescription therapy with the convenience of consumer electronics by serving the patients as a direct distributor. The company recently announced completing enrollment in the largest therapeutic study ever conducted in essential tremor in the US, the landmark PROspective study for SymPtomatic relief of Essential tremor with Cala Therapy (PROSPECT).

About Cala Health, Inc.

Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. The company’s wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation. The first indication for Cala Health’s wearable therapy is essential tremor, a disease experienced by more than seven million people and characterized by severe hand tremors. New therapies are under development in neurology, cardiology, and psychiatry. The company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology. For more information, please visit www.calahealth.com.

Contacts

Media Contact:
Terri Clevenger
terri.clevenger@icrinc.com
(203) 856-4326

Categories: News

Tags:

TPG agrees to sell Cancer Treatment Services International to Varian Medical Systems

TPG Capital

Mumbai and San Francisco – May 20, 2019 – TPG Growth, the middle market and growth equity platform of alternative asset firm TPG, announced today that it has signed a definitive agreement to sell Cancer Treatment Services International (CTSI) to Varian Medical Systems (NYSE: VAR) for $283 million. CTSI is part of Asia Healthcare Holdings (AHH), a healthcare operating platform founded by TPG Growth. The transaction is expected close approximately two weeks and is subject to customary closing conditions.

CTSI owns and operates an expanding network of cancer treatment facilities across India and South Asia, including several brands: the American Oncology Institute, CTSI’s flagship network comprised of multi-disciplinary radiation, medical, and surgical oncology focused cancer hospitals across South Asia; US-based CTSI Oncology Solutions, which provides cancer treatment planning services to healthcare providers worldwide; and AmPath, an integrated reference laboratory and pathology services provider in India. CTSI employs more than 1,500 people across its operations in India and the US, and fulfills a significant patient demand in the region for quality cancer treatment protocols.

“We invested in CTSI in 2016 with the belief that the company was in a strong position to address a substantial and growing need for quality cancer care in India. Today, CTSI is one of the largest and leading providers of high-quality oncology services across the country and broader South Asia,” said Matthew Hobart, Partner at TPG Growth. “CTSI’s growth story is an example of what we are trying to achieve through AHH, which is to provide dynamic single-specialty healthcare companies the resources and expertise to meaningfully build and scale their businesses. The transaction today marks an exciting step for CTSI and an important milestone in AHH’s evolution as one of the leading healthcare platforms in South Asia.”

When CTSI was first acquired by TPG Growth, it operated one facility in Hyderabad, India. In just three years, with AHH’s support and the onboarding of a highly talented management team, the company has grown to a network of 11 cancer hospitals with a pipeline of six more hospitals under execution. The success of CTSI builds on the track record of TPG’s healthcare investing franchise around the world, which has invested $14 billion of equity in the sector. More than 20 percent and approximately $3 billion of equity has been invested outside the US, across leading healthcare delivery networks including Parkway Holdings (Singapore), Healthscope (Australia), Manipal Health (India), Asiri Health (Sri Lanka), and United Family Healthcare (China).

“The genesis of AHH was to build single-specialty healthcare delivery businesses. Majority positions in these early stage entities give our team the unique opportunity to mold the future of these companies by giving them the right management teams, capitalization, and profitable growth trajectory. CTSI validates this unique approach to Indian healthcare,” said Vishal Bali, CEO of Asia Healthcare Holdings. “Leveraging TPG’s global healthcare franchise, we worked together to grow CTSI from sourcing to exit.”

AHH seeks to build a market-leading franchise in single-specialties across India and South Asia, and helps power companies through a single management team. AHH’s operation is unique to Indian healthcare and unparalleled in the region. Recently, AHH acquired Nova Fertility and its network of 20 IVF centers which, when combined with AHH’s existing network of 12 Women & Children hospitals under the Motherhood brand, will be India’s largest mother and child-focused healthcare platform in India.

TPG Growth

TPG Growth is the middle market and growth equity investment platform of TPG, the global alternative asset firm. With approximately $12.8 billion of assets under management, TPG Growth targets investments in a broad range of industries and geographies. TPG Growth has the deep sector knowledge, operational resources, and global experience to drive value creation, and help companies reach their full potential. The firm is backed by the resources of TPG, which has more than $104 billion of assets under management. For more information, visit www.tpg.com.

About CTSI

CTSI is a provider of university-level, comprehensive treatment for cancer patients. Founded by physicians and businessmen with substantial experience in the development, operation and networking of cancer services, CTSI provides innovative and technologically advanced treatment solutions through an IT-based model that allows integration and centralization of core services. The company began international operations at its flagship cancer hospital in Hyderabad, India in 2013 and currently has several operational cancer centers and ongoing development projects. For more information, visit http://www.cancertreatmentservices.com.

 

Categories: News

Tags:

Gimv hands Benedenti back to its founders following growth trajectory in Belgian dental care

GIMV

17/05/2019 – 17:45 | Portfolio

At the end of 2015, Gimv acquired a minority stake in Benedenti, a group of multidisciplinary dental practices in Flanders, Belgium. Founded in 1985 as a private dental practice in Herentals by Rik Claes and his wife Griet Luyten, the practice has grown over the years first into a large group practice and then – with Gimv’s support – into a group with eight branches. In September 2018, the new state-of-the-art group practice and headquarters opened in Herentals. With 15 (treatment) chairs, this is one of the largest group practices in Flanders.

By developing multidisciplinary group practices, Benedenti responds to a range of challenges facing dental care in Flanders, such as a substantial number of practising dentists rapidly approaching retirement age, an insufficient influx of new graduates ready to enter professional practice and the emergence of dental hygienists. Other factors include the many technological and scientific developments in the field of dentistry and changing expectations of patients and dentists. Accessible, high-quality dental care is at the heart of the group’s expansion and the continuing professionalisation of the group practices.

Through Gimv’s involvement and driven by the current CEO and founder Rik Claes, extra resources have been put into forming partnerships with other dental practices, developing new group practices and continuing to invest in the latest technology. The number of employees has evolved from around 50 in 2015 to nearly 150 today and, through a team of 60 dentists, Benedenti Group is able to offer all dental specialisms.

Gimv announces today that it is selling back its stake to the founding Claes family.

Bart Diels, Head Gimv Health & Care, explains: “We’re glad that we’ve been able to support Benedenti and the Claes family with the continuing expansion and professionalisation of the group. Led by the family, Benedenti will continue to grow organically from a strong base, with a quality-focused culture, dedicated dentists & staff and a unique DNA.”

Rik Claes, CEO Benedenti Group, adds: “We look back with satisfaction on our partnership with Gimv. Thanks to their input, we’ve been able to expand and professionalise Benedenti further. Now we want to stand on our own two feet again. It’s our goal for Benedenti Group to remain in the hands of dentists in the long term, and to continue growing strongly into an outstanding, recognisable group for staff and patients.”

The yield on Benedenti over the entire investment period is in line with Gimv’s long-term average. No further financial details, however, are provided on the transaction itself.

Categories: News

Tags:

Ampersand Capital Partners completes Growth Equity Investment in Transplantation Diagnostic firm GenDx

Utrecht, Netherlands – May 8, 2019 – Genome Diagnostics B.V. (“GenDx”) announced today that Ampersand Capital Partners has completed a minority, growth equity investment in the company. Wietse Mulder, PhD., remains the majority shareholder and CEO of GenDx. The partnership between Ampersand and GenDx aims to foster sustainable growth, both organically and through M&A activities in the molecular diagnostic products and services market.

GenDx is a leading provider of molecular diagnostic kits and analysis software for transplantation and companion diagnostics. Dr. Mulder commented: “GenDx has been successfully organized as a fully independent organization for almost fifteen years. We are delighted to partner with Ampersand and together continue to live by our vision of ‘meaningful entrepreneurship’ by offering the best products, education, and services to the transplantation community worldwide.”

David Parker, a General Partner at Ampersand, added: “Given Ampersand’s prior experience in the transplantation and NGS markets, we were highly impressed by the differentiated product and service offering of GenDx. We are excited to partner with Dr. Mulder and the GenDx team to build on the company’s long history of profitable growth.”

In connection with this transaction, David Parker has joined the GenDx Board of directors along with Ampersand Operating Partner Mike Evans, PhD. They join three founders on the GenDx Board: Dr. Mulder, Raoul Linschoten, LLM (Chairman), and Oscar Schoots, PhD. The board will be supported by non-director advisors Larry McCarthy, PhD and Frank Witney, PhD., both seasoned entrepreneurs and executives who serve as Operating Partners at Ampersand.

About GenDx

Genome Diagnostics B.V., also known as GenDx, is a Dutch company specialized in Molecular Diagnostics, focused on development, production and sales of innovative assays and analysis software for transplantation and companion diagnostics.

GenDx specializes in HLA sequencing-based typing strategies and offers reagents and software for both Sanger and NGS approaches. In 2013, GenDx started developing and distributing products for chimerism monitoring by qPCR. Thanks to its extensive in-house expertise, GenDx also offers custom laboratory services for basic and clinical research organizations. GenDx organizes dedicated HLA SBT and chimerism monitoring training courses worldwide on a regular basis for lab directors, lab managers, scientists and technicians working in tissue typing laboratories, blood banks, and donor registries.

GenDx is based at the University Science Park in Utrecht, the Netherlands and was founded in 2005 by Erik Rozemuller PhD, Wietse Mulder PhD and UMC Utrecht Holdings B.V. represented by Oscar Schoots PhD and Raoul Linschoten LLM. Further information about GenDx can be found at www.GenDx.com.

GenDx has also an office near O’Hare airport, Chicago, IL (USA).

About High-Resolution HLA Typing

The Human Leukocyte Antigen (HLA) system consists of a large family of highly variable genes and allelic variants which form the basis of the human immunological defence system. In stem cell transplantation matching patient and donor is vital as small differences between HLA alleles may have serious effects on the outcome of transplantation. High-resolution typing is a technology which enables determination of even the smallest variations in nucleotides, making it ideal for stem cell transplantation purposes.

Until recently, Sanger sequencing-based HLA typing was considered as the golden standard for high-resolution typing. GenDx offers SBTexcellerator® and AlleleSEQR® together with the software package SBTengine® for carrying out Sanger based sequencing HLA typing. Next Generation Sequencing has become the new golden standard for HLA typing, as data analysis using NGS is becoming easier and faster to interpret and this technique is suitable for higher throughput. GenDx offers NGSgo® reagent line together with the software package NGSengine® for carrying out NGS based HLA typing.

About Chimerism Monitoring

After stem cell or bone marrow transplantation, both donor and recipient cells can be detected in the recipient’s blood (chimeric status). Monitoring the chimeric status allows for the detection of recipient cells returning over time, which can possibly lead to a relapse state. GenDx has been offering KMRtype/KMRtrack reagents since 2013.. Currently, the CE-IVD marked set contains 39 assays based on bi-allelic insertions/deletions and SNPs. Software package KMRengine generates a laboratory protocol, qPCR machine sample setup sheet, and data tracking for each recipient/donor couple over time.

About Ampersand Capital Partners

Founded in 1988, Ampersand is a middle market private equity firm dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of its core healthcare sectors, including Avista Pharma Solutions, Brammer Bio, Confluent Medical, Genewiz, Genoptix, Talecris Biotherapeutics, and Viracor-IBT Laboratories. Additional information about Ampersand is available at www.ampersandcapital.com.

GenDx Netherlands
Yalelaan 48
3584 CM Utrecht
Office: +31 30 252 3799
E-mail: info@gendx.com

Contact GenDx
Wietse Mulder PhD
CEO
Email: w.mulder@gendx.com
Phone: +31 30 252 3799

NGSgo®, NGSengine®, KMRtype®, KMRtrack® and KMRengine® are registered trademarks of GenDx. GenDx is a registered trade name of Genome Diagnostics B.V.

Categories: News

Tags:

Baird Capital Announces Sale of Hopebridge, Retains Minority Stake

Baird Capital

CHICAGO – May 8, 2019 – Baird Capital, the direct private investment arm of Baird, recently announced the sale of Hopebridge LLC (Hopebridge) to Arsenal Capital Partners. Baird Capital will retain a minority stake in the company. The financial terms of the deal were not disclosed.

Headquartered in Indianapolis, Hopebridge was founded in 2005 to serve the growing need for autism treatment services and to improve the lives of affected children and families. The company is committed to providing personalized outpatient ABA, occupational, speech, and feeding therapies for children touched by autism spectrum disorder and behavioral, physical, social, communication and sensory challenges. Hopebridge continues to open state-of-the-art autism therapy centers in new communities to reach patients and families who need services. With locations in Georgia, Indiana, Kentucky and Ohio, Hopebridge expects to operate 41 centers by June 2019, compared to 14 at the time of Baird’s initial 2017 investment.

“Baird Capital is fortunate to have worked with Hopebridge and its talented leadership team, and we are pleased to continue supporting the company’s future growth,” said Mike Bernstein, Partner, Baird Capital.

About Baird Capital
Baird Capital makes venture capital, growth equity and private equity investments in strategically targeted sectors around the world. Having invested in more than 300 companies over its history, Baird Capital partners with entrepreneurs and, leveraging its executive networks, strives to build exceptional companies. Baird Capital provides operational support to its portfolio companies through teams on the ground in the United States, Europe and Asia, a proactive portfolio operations team and a deep network of relationships, which together strive to deliver enhanced shareholder value. Baird Capital is the direct private investment arm of Robert W. Baird & Co. Incorporated. For more information, please visit BairdCapital.com.

For additional information, contact:
Baird Public Relations 
414-765-7250

Categories: News

Tags: